Study record · NAD+
Six-hour intravenous NAD+ metabolome pilot
The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.
Key result
The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.
Study details
Study designPilot controlled human infusion study
PopulationAdults receiving NAD+ or saline
Sample size11
RouteIntravenous infusion
Regimen / exposure750 mg NAD+ over 6 hours (~3 micromol/min)
Duration6 hours
ComparatorSaline control (3 participants)
Primary endpoint / questionPlasma/urine NAD+ metabolome and tolerability
Safety resultNo observable adverse events were reported in the NAD+ cohort during the infusion period.
Key limitationsVery small sample; pharmacokinetic/metabolomic study, not a therapeutic efficacy trial.
Registry / identifierDOI 10.3389/fnagi.2019.00257